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Background:  Despite multi-modality therapy, the majority of patients with metastatic or 
recurrent Ewing sarcoma (ES), the second most common pediatric bone malignancy, will die of 
their disease. ES tumors express aberrantly activated ETS transcription factors through 
translocations that fuse the EWS gene to ETS family genes FLI1 or ERG. The aberrant activation 
of ETS transcription factors promotes malignant transformation and proliferation. While, FLI1 or 
ERG cannot be readily targeted, there is an opportunity to deploy functional genomics screens, to 
develop novel therapeutic approaches by identifying targetable liabilities in EWS/FLI1 dependent 
tumors.  
Materials and Methods: We performed a near whole-genome pooled shRNA screen in a panel 
of five EWS/FLI1 dependent Ewing sarcoma cell lines and one EWS/ERG cell line to identify 
essential genes. Essential genes were defined as those genes whose loss resulted in reduced 
viability selectively in ES cells compared to non-Ewing cancer cell lines. Essential hits were 
subsequently validated with genomic knockdown and chemical inhibition in vitro, followed by 
validation of the on-target effect of chemical inhibition. Next, we determined the in vivo effects 
of small-molecule inhibition on survival and tumor growth in NOD scid gamma (NSG) mice 
with established subcutaneous ES xenografts.  
Results: Top hits in our screen that could be readily targeted by small-molecule inhibitors, and 
thus have potential for rapid clinical validation, were selected for further investigation. These 
hits included IKBKE, CCND1 and CDK4. IKBKΕ, a non-canonical IKK with an oncogenic role 
in breast cancer, was one of the top kinase hits in the screen. IKBKΕ shares significant 
homology to TBK1, another non-canonical IKK that is essential in k-RAS dependent lung 
cancer. We validated IKBKE through small-molecule inhibition of IKBKE/TBK1 and shRNA 
based knockdown.  Ewing sarcoma cell lines are sensitive to low micromolar concentrations of ! 3 
two IKBKE/TBK1 inhibitors (CYT387 and MRT67307). Additionally, in a panel of ES cell 
lines, knockdown of IKBKE resulted in decreased growth and impaired colony formation. These 
observations, paired with impairment of NF-κB nuclear localization following CYT387 
treatment suggests that non-canonical IKK mediated signaling may be essential in Ewing 
sarcoma. We further validated these results through inhibition of IKBKE/TBK1 in in vivo 
xenograft models treated with 100 mg/kg/day of CYT387. Treatment over the course of twenty-
nine days resulted in a significant increase in survival (p-value = 0.0231) and a significant 
decrease (p-value = 0.036) in tumor size after fifteen days of treatment.  
CDK4 and CCND1 are highly expressed in Ewing sarcoma as compared to other tumor 
types. shRNA mediated knockdown of CDK4 and CCND1 resulted in impaired viability and 
anchorage independent growth. Furthermore, treatment of Ewing sarcoma cell lines with a highly 
selective CDK4/6 inhibitor, LEE011, resulted in decreased viability (IC50 range of 0.26-18.06 
µM), potent G1 arrest in six of eight EWS/FLI1 containing Ewing sarcoma lines tested and 
apoptosis in a panel of four highly sensitive lines. Administration of 75 mg/kg/day and 250 
mg/kg/day of LEE011 in NSG mice with Ewing xenografts resulted in significant impairment of 
tumor growth, (p-value <0.001 for both treatment arms), as compared to vehicle control.   
Conclusions: These studies suggest a role for the targeting of IKBKE and CDK 4/6 in Ewing 
sarcoma, findings with immediate clinical relevance for patients with this malignancy, because 
small-molecule inhibitors of these proteins have already entered clinical trial for other disease 
indications.  ! 4 
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Glossary of abbreviations:  
 
Akt: also known as protein kinase B 
ATP: Adenosine triphosphate 
CCND1: Cyclin D1 
CDK4: Cyclin-dependent kinase 4 
CD99: Cluster of differentiation 99, also known as MIC2 
CYLD: cylindromatosis gene  
cIAP: cellular Inhibitor of Apoptosis 
EFT: Ewing sarcoma family of tumors  
ERG: ETS-related gene 
ES: Ewing sarcoma  
ETS: E26 Transformation-specific transcription factor or Erythroblast transformation-specific 
transcription factor 
EWS: Ewing sarcoma gene 
FLI1: Friend leukemia integration 1 transcription factor, also known as transcription factor 
ERGB 
IC50: Fifty percent inhibitory concentration 
ID2: Inhibitor of DNA binding 2 
IκBα: Inhibitor of kappa B (κB) 
IKBKA: Inhibitor of kappa B (κB) kinase alpha, also known as IKKα 
IKBKB: Inhibitor of kappa B (κB) kinase beta, also known as IKKβ 
IKBKE: Inhibitor of kappa B (κB)kinase epsilon, also known as IKKε or IKK-i 
IKK: Inhibitor of kappa B (κB) kinase  
MEF: Mouse embryonic fibroblasts  ! 6 
NF-κB: Nuclear factor-kappa B (κB) 
NKX2.2: NK2 Homeobox 2 
NR0B1: Nuclear Receptor Subfamily 0, Group B, Member 1, also known as DAX-1 
NSG: Nod-SCID-gamma mice 
PARP-1: Poly [ADP-ribose] polymerase 1, also known as NAD+ ADP-ribosyltransferase 1 
PI: Propidium iodide 
RPM: Revolutions per minute  
shRNA: small hairpin RNA 
TANK: TRAF family member NF-κB activator  
TBK1: TANK-binding kinase 1 
TRAF2: TNF receptor associated factor 2 
TRAF6: TNF receptor associated factor 6 ! 7 
Introduction 
 
Ewing sarcoma (ES) is the second most common pediatric bone malignancy in the United 
States. Despite advances in treatment of primary ES, the disease continues to have very poor 
survival for patients with metastatic or relapsed disease, even with multi-modality therapy.
1,2  
ES represents a spectrum of tumors belonging to Ewing sarcoma family of tumors (EFT). 
These tumors are often located in diaphyses of long bones and appear as undifferentiated “small 
round blue cells” on histological examination. EFT also include chest wall tumors (Askin 
tumors) and atypical ES.
3 EFT share similarities not only in histology, but also in molecular 
biology, as they are characterized by balanced chromosomal translocations that define the 
biology of the disease.
4 Characteristic translocations involve fusion of EWS with ETS 
transcription factor-encoding genes. The most common translocation, present in 85% of Ewing 
sarcoma, involves chromosome t(11;22) which results in the fusion of the 5’ end of the 
transcriptional regulator encoding gene EWS with the 3’ region of the transcription factor 
encoding gene FLI1.
5 The resultant, aberrantly expressed 72-kDa-fusion protein is a nuclear 
protein that retains DNA-binding activity, recognizing the GGAA Ets- family DNA binding 
site.
6 Another 5-10% of ES and related tumors can also arise from a second chromosome 
translocation, t(21;22), that fuses EWS with the ETS family transcription factor encoding gene 
ERG, resulting in the fusion protein (EWS/ERG).
7 
EWS/FLI1 promotes transformation and tumorigenesis in Ewing sarcoma 
EWS/FLI1 expression is oncogenic with cDNA transcripts of EWS/FLI1 capable of 
transforming NIH-3T3 cells, while absence of the EWS or FLI1 domain from the cDNA 
transcript abrogates this phenotype.
8 NIH-3T3 cells that express EWS/FLI1 result in accelerated 
tumor formation in immunocompromised mice. Additionally, dominant negative and RNA 
interference studies have demonstrated a dependence of Ewing sarcoma cells on the EWS/FLI1 ! 8 
fusion protein.
9,10 The fusion of EWS/FLI1 results in an aberrant transcription profile in which 
the N-terminal EWS domain promotes greater transcriptional activation than the native FLI1 
protein alone and the intact DNA-binding domain of FLI1 within EWS/FLI1 results in 
localization of the protein to GGAA containing promoter or enhancer sites on target genes.
11  
Targets of EWS/FLI1 as mediators of Ewing sarcoma oncogenesis    
Several targets of EWS/FLI1 have been identified and among these regulated genes, 
some have been shown to promote the oncogenic phenotype of Ewing sarcoma. For example, 
EWS/FLI1 expression results in overall gene downregulation that has been attributed to the 
direct activation of transcriptional repressors, such as NKX2.2 and NR0B1, by EWS/FLI1.
9,12,13 
Additional direct targets of EWS/FLI1 that play a role in ES oncogenesis include the cell surface 
marker CD99 and inhibitor of DNA binding 2 (ID2). CD99, also known as MIC2, is a 32 kDa 
integral membrane glycoprotein that is used as a histologic marker for the diagnosis of Ewing 
sarcoma. It has been shown to be essential for Ewing transformation, with decreased expression 
of CD99 in patient derived Ewing cells resulting in abrogation of the transformation phenotype. 
The knockdown of CD99 also inhibits neural differentiation and results in G2 arrest with an 
increase in apoptosis.
14 ID2 has been shown to be upregulated in several tumor types including 
colon and pancreatic adenocarcinoma as well as neuroblastoma. The upregulation of ID2 in these 
tumor types is mediated by c-Myc, N-myc or β-catenin, while it has been linked to EWS/FLI1 in 
ES. Functionally, ID2 acts as an antagonist of basic helix-loop-helix proteins and regulates the 
switch between cell proliferation and differentiation.
15  
Aberrations in G1 checkpoint regulation in Ewing sarcoma 
Another important target of EWS/FLI1 mediated transformation in cyclin D1. EWS/FLI1 
has been shown to regulate cyclin D1 expression with inhibition of EWS/FLI1 resulting in a 
decrease of cyclin D1 and an increase of cyclin D3. The induction of EWS/FLI1 in a ! 9 
rhabdomyosarcoma cell background, which classically has increased cyclin D3 and an absence 
of cyclin D1, results in increased cyclin D1 expression and decreased cyclin D3 expression.
16 
Notably, EWS/FLI1 increases expression of an oncogenic variant of cyclin D1, referred 
to as cyclin D1b, due to alteration of transcription mechanics from truncation of EWS in the 
EWS/FLI1 fusion protein. Wild type EWS is a member of the RNA- and DNA- binding TET 
family of proteins that is involved in transcriptional regulation and RNA splicing.
17 EWS binds 
and interacts with transcription and splicing machinery and favors D1a isoform expression, 
however the fusion protein EWS/FLI1, with a truncated transcriptional regulator EWS protein, 
favors D1b isoform expression, mediated through slowing of transcription elongation.
18,19  
EWS/FLI1 further influences cell cycle progression through other G1 regulatory genes. 
Antisense oligonucleotide mediated downregulation of EWS/FLI1 contributed to decreased 
expression of cyclin D1 and cyclin E, while expression of cyclin-dependent kinase inhibitors of 
the G1-S transition, p21 and p27, was increased. Transfection of EWS/FLI1 into NIH-3T3 cells 
resulted in the converse phenomenon.
20 Finally, loss of p16, a cyclin-dependent kinase inhibitor, 
is a frequent mutational event found in up to 30 percent of Ewing family of tumors and is 
associated with worse prognosis.
21 The multiple roles of EWS/FLI1 in activating mediators of 
G1 cycle progression, promoting cylin D1b expression and suppressing inhibitors of the G1-S 
transition, suggest that these pathways may be attractive therapeutic liabilities in Ewing sarcoma.    
The role of NF-κB signaling in Ewing sarcoma 
In addition to direct targets of EWS/FLI1 as mediators of Ewing oncogenesis, other 
signaling pathways have been identified that play an important role in Ewing sarcoma survival 
and growth.  
The NF-κB pathway is known as a transcription factor involved in immune and 
inflammatory pathways. NF-κB is composed of five family members of proteins that are grouped ! 10 
based on those that require proteolytic processing for activation and those that do not. RelA/p65, 
c-Rel and RelB proteins do not require proteolytic processing while NF-κB1 (p105) and NF-κB2 
(p100) are processed to active forms p50 and p52, respectively. RelA/p65 and c-Rel proteins 
most frequently dimerize. Extrinsic, autocrine or instrinsic activation of the IKK complex can 
result in phosphorylation and proteolytic degradation of the NF-κB inhibitory protein, IκBα 
which binds to the nuclear localization sequence of NF-κB homo or hetero-dimers and blocks 
their nuclear localization.
22 In contrast, RelB, a NF-κB protein that is expressed mainly in 
lymphoid tissue dimerizes with NF-κB2 (p100) and requires proteolytic processing to allow for 
nuclear localization of the p52-RelB dimers.
22  
Dimers composed of RelA/p65, c-Rel and p50 are under the regulation of the canonical 
or non-canonical IKKs. Canonical IKKs include a complex of catalytic IKK proteins IKBKB and 
IKBKA as well as the regulatory subunit IKKγ/NEMO. In contrast, the non-canonical IKK 
proteins, IKBKE and TBK1 act independently to promote NF-κB activation
23,24, and play roles 
in cellular signaling involving activation of the anti-viral interferon response and Akt 
activation.
25  
The NF-κB family of proteins have been intensively studied for their role in 
inflammation and the innate immune response, in which NF-κB transcription factors express 
target genes involved in cell proliferation, survival and migration. Recent evidence suggests that 
aberrations in regulation of NF-κB signaling or chronic inflammation are associated with 
tumorigenesis.
22,26,27  
Numerous mechanisms underlie NF-κB mediated tumorigenesis but can include 
uncoupling of NF-κB transcription factors from the intricate and precisely controlled inhibitory 
regulators, autocrine or paracrine production of cytokines stimulating expression of NF-κB 
proteins as well as chronic infection and inflammation. Activation of NF-κB target genes results ! 11 
in stimulation of cell proliferation through cytokine expression, expression of cyclin D1 and 
inhibition of apoptosis in response to genotoxic stress secondary to increased expression of 
cellular inhibitors of apoptosis (cIAPs) and BCL2 family member proteins. Increased 
angiogenesis and metastatic potential are also features of NF-κB transcriptional activation, 
mediated by expression of matrix metalloproteinases as well as angiogenic factors such as IL-8 
and vascular endothelial growth factor (VEGF).
22  
In the cellular context of Ewing sarcoma, NF-κB signaling has been described to induce 
resistance to apoptotic stimuli.
28 Further, a role for NF-κB in mediating Ewing sarcoma 
turmorigenesis was suggested when expression of a degradation-resistant form of an inhibitor 
(IκBα) of NF-κB resulted in decreased tumorigenicity of Ewing sarcoma cells, with decreased 
ability to generate tumors in nude mice.
29  
Defining and targeting mediators of oncogenesis in EWS/FLI1 transformed cells 
The central role of EWS/FLI1 in orchestrating expression of oncogenic mediators in 
Ewing sarcoma makes it an attractive therapeutic target; however, such therapies are difficult to 
develop. Transcription factors have remained poor targets for drug development due to the broad 
roles of transcription factors in normal tissue as well as tumor cells, and the challenges of 
designing therapeutic compounds that can localize to the nucleus. 
30 Strategies to identify Ewing 
sarcoma specific tumor liabilities are necessary to develop improved targeted therapies. One 
such approach involved a large-scale screen of several hundred-cancer cell lines with 130 
preclinical and clinical drugs to identify tissue-specific sensitivity and associations between 
cancer genes and cellular response. This screen resulted in the identification of marked 
sensitivity of Ewing sarcoma to PARP-inhibitors.
 24 Further investigation of the mechanism 
underlying sensitivity of PARP inhibition extended our understanding of Ewing sarcoma 
biology, demonstrating that Ewing cells have greater foci of double strand breaks per cell even ! 12 
when compared to other ETS mediated tumors, such as prostate cancer cell lines expressing 
TMPRSS2-ERG. 
31,32  
To identify novel Ewing sarcoma tumor specific liabilities, we have conducted a near-
whole genome functional shRNA screen of five EWS/FLI1 expressing Ewing sarcoma lines, 
compared to over 200 non-Ewing cancer cell lines. Candidate tumor specific liabilities were 
validated by shRNA knockdown and chemical inhibition in vitro and in vivo. ! 13 
Materials and Methods: 
 
shRNA screen and analysis  
In collaboration with the Broad Institute and as a part of Project Achilles 
(http://www.broadinstitute.org/achilles)
33, a near whole genome pooled shRNA screen was 
performed in five EWS/FLI1 rearranged Ewing sarcoma cell lines (A673, EW8, EWS502, TC71 
and TC32) and one EWS/ERG rearranged cell line (CADO-ES-1). The screen involved a total of 
223 cell lines from 22 cancer types and was performed with an shRNA library of 55,541 
barcoded shRNAs in lentiviral vectors targeting 13,882 genes.
33 Cells were infected at a 
multiplicity of infection of 0.1 and cultured following infection for at least 16 doublings. DNA 
from cells was then collected and sequenced to quantify the abundance of each shRNA, with 
depleted shRNAs hypothesized as targeting essential genes. Quality control tests were applied to 
remove replicates that failed quality control measures, along with overlapping shRNAs and 
shRNAs with low counts in DNA samples. All Ewing cell lines, except TC32, and 211 other 
tumor lines passed the quality control tests. Filtered quality controlled data were presented as 
ZMAD scores genome-wide normalized per individual cell line. 
In order to prioritize targets that are uniquely essential for the proliferation and survival 
of Ewing sarcoma cell lines, we tested the differential expression of the shRNAs in Ewing versus 
other cancer cell lines that display low functional similarity with Ewing sarcoma. Functional 
non-similarity with Ewing sarcoma was estimated based on a consensus of published EWS/FLI1 
gene signatures
13,34,35 and principle components analysis applied on Achilles matched gene 
expression data. 
To determine whether a given shRNA contributes to the observed essentiality phenotype 
between Ewing and non-similar Ewing classes, we used a weight of evidence (WoE) approach. 
This approach computes the likelihood that a given shRNA has the ability discriminate between ! 14 
the two classes of interest in a statistically significant manner. Weights of evidence scores for a 
particular class comparison, as defined by a class definition file, were calculated using the 
GenePattern module “ScorebyClassComp.”
36 
The RIGER module implemented in the GENE-E program 
(http://www.broadinstitute.org/cancer/software/GENE-E), was used to collapse shRNA 
differential essentiality scores to gene rankings by the weighted sum of the best two hairpins 
method.
37 The top gene hits identified based on the RIGER method were then filtered out for 
expression based on the z-score threshold of 1.0 in the RNASeq Ewing sarcoma cell line and 
tumor data available through the SIGMA Project (Stegmaier Lab).  
Cell lines and chemical compounds 
A673, EW8, SKNEP, EWS834 and RDES cells were grown in Dulbecco’s Modified 
Eagle’s Media (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich) and 10 units/mL of penicillin, 10 µg/mL streptomycin and 30 µg/mL of L-Glutamine, 
(PSQ, Thermo Fisher Scientific). A673 cells were cultured in media supplemented with 1 
mmol/L of sodium pyruvate (Life Technologies). CADO-ES-1, TTC466 and EWS502 cell lines 
were cultured in RPMI 1640 media (Life Technologies) supplemented with 15% FBS and PSQ. 
TC71 and TC32 lines were cultured in 10% RPMI1640 and PSQ media.  
Cell lines were kindly provided by Dr. Todd Golub (Broad Institute, Cambridge, MA) 
except for EWS502 and EWS834, which were gifts from Dr. Jonathan Fletcher (Brigham and 
Women’s Hospital, Boston, MA). All cell lines have been confirmed to have an EWS/FLI1 or 
EWS/ERG rearrangement by RNA sequencing. All cell lines were cultured at 37°C in a 
humidified atmosphere containing 5% CO2. Chemical compounds utilized included the JAK1/2 
and IKBKE/TBK1 inhibitor CYT387 (Selleck Chemicals), an IKBKE/TBK1 inhibitor 
MRT67307, kindly gifted by Dr. David Barbie (Dana-Farber Cancer Institute, Boston, MA), a ! 15 
sesquiterpine lactone inhibitor of IKBKB, parthenolide (Selleck Chemicals), a JAK 1/2 inhibitor, 
Ruxolitinib (Selleck Chemicals), Akt inhibitor MK-2206 (Selleck Chemicals) and the PI-3K 
inhibitor GDC-0941 (Selleck Chemicals). Ewing sarcoma cell lines were also treated with the 
CDK4/6 inhibitor LEE011, gifted to us from Novartis Oncology (Cambridge, MA), and PD-
0332991 (Selleck Chemicals). Compounds were dissolved in DMSO and stored at 10 mmol/L 
stock concentrations at -20°C for up to several months for in vitro experiments.  For in vitro drug 
treatments, Ewing sarcoma cell lines were plated in 6-well or 10 cm tissue culture plates, 
allowed to adhere over 24 hours and subsequently treated with the above listed compounds.  
Determination of cell viability and colony formation 
Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay 
(Promega) that measures ATP content as a surrogate for cell number. Luminescent readings were 
obtained using the FLUOstar Omega microplate reader (BMG Labtech). For small-molecule 
treatments, cells were seeded at a density of 1.25 x10
3 cells per well in a 384-well plate 
(Corning). Cells were treated at a range of concentrations and IC50 values were calculated from 
ATP luminescence measurements after five days of treatment using log-transformed, normalized 
data in GraphPad Prism 5.0 (GraphPad Software, Inc.). Cell viability was also determined 
following shRNA-tranduction of Ewing sarcoma cells. After seeding 1.25x10
3 cells per well in a 
384-well plate, ATP content was measured at day 3, 5, 6 and 8 after transduction.  
Colony formation assays were performed by dissolving 5 x10
3 cells into 2 mL of 
methylcellulose matrix (ClonaCell-TCS Medium, Stemcell Technologies) and subsequently 
plating them into gridded 6-cm plates (Thermo Fisher Scientific) and incubated for 10 to 15 
days. Colonies were counted from 100 squares using a Nikon inverted microscope. All samples 
were plated in duplicate.   
Cell Cycle analysis and Apoptosis ! 16 
The effect of small-molecule treatment on Ewing sarcoma cell cycling was measured at 
72 and 120 hours post-treatment.  Cells were harvested, washed in PBS, suspended in 200 µL of 
PBS and fixed with 4 mL of cold 70% ethanol added drop-wise. Tubes were stored at -20°C for 
up to one week prior to analysis. Tubes were centrifuged at 500g for 10 minutes and washed with 
PBS before being re-suspended in 200-500 µL of staining buffer containing 40 µg/mL of 
propidium iodide (Sigma Aldrich) and 100 µg/mL of RNase A (Qiagen). Samples were 
incubated in the dark for at least fifteen minutes before analysis on a FACSCanto II analyzer. 
Data analysis was completed using Flowjo 7.6 Software (Treestar, Ashland OR, USA).  
Ewing sarcoma cells lines were assessed for apoptosis after small-molecule treatment for 
72 hours to up to 120 hours post-treatment. Apoptosis was assessed using flow cytometric 
analysis of annexin V and propidium iodide staining (eBioscience). Following drug treatment, 
cells were harvested, washed with phosphate-buffered saline (PBS) and annexin binding buffer 
(eBioscience) before incubation with annexin V-APC, washed with annexin binding buffer and 
stained with propidium iodide.  
Western blotting 
Protein Extraction: Whole cell lysates were prepared following small-molecule treatment 
or six days after shRNA transduction. Cells were washed with PBS, trypsinized and lysed using 
1x Cell Lysis Buffer (Cell Signaling) supplemented with EDTA-free protease inhibitors 
(Complete Mini) and PhosSTOP phosphatase inhibitors (Roche). Lysates were incubated with 
cell lysis buffer for fifteen minutes and centrifuged at 13,000 rpm for fifteen minutes at 4°C. 
Supernatants were removed and evaluated for protein concentration using the Bradford method 
(Bio-Rad Protein Assay Dye Reagent Concentrate).  
Nuclear extraction: Nuclear extracts were prepared using a nuclear extraction kit from 
ActivMotif. Ewing sarcoma cells, grown in a 10-cm tissue culture plate, were washed with ice-! 17 
cold PBS containing phosphatase inhibitors and harvested with a cell-scraper in 3 mL of PBS 
with phosphatase inhibitors. Cells were spun down at 500 rpm for five minutes and incubated on 
ice for ten minutes with a hyptonic buffer. The cell membrane was then disrupted with addition 
of detergent and gentle agitation. The cytoplasmic subfraction was separated with centrifugation 
at 13,000 rpm for one minute and aspirated away from the nuclear pellet. The nuclear pellet was 
washed with hypotonic buffer before being resuspended in complete lysis buffer containing 
protease inhibitors and DTT. Following thirty minutes of incubation on ice with complete lysis 
buffer, nuclear protein was separated from the remaining sub-cellular pellet with centrifugation 
at 13,000 rpm for ten minutes. Supernatants were removed and evaluated for protein 
concentration using the Bradford method (Bio-Rad Protein Assay Dye Reagent Concentrate). 
Immunoblotting: Lysate concentrations were standardized and resolved on 4-12% Nu-
PAGE Bis-Tris gels (Life Technologies) and electrophoretically transferred to Immobilon-P 
PVDF membrane (Millipore) activated in methanol. Membranes were blocked in 5% bovine 
serum albumin (BSA) diluted in TBS-tween and hybridized using primary antibodies diluted in 
5% BSA TBS-Tween and 0.1% sodium azide.  
Antibodies utilized: Primary antibodies utilized included PARP-1 (Cell Signaling), 
GAPDH (Santa Cruz), Vinculin (Abcam), IKBKE (Sigma Aldrich), TBK1 (Cell Signaling), 
IκBα (Cell Signaling), NF-κB p65 (Cell Signaling), NF-κB p50 (Santa Cruz), NF-κB p52 (Santa 
Cruz), c-Rel (Cell Signaling), Rel B (Cell Signaling), CDK4 (Thermo Fisher Scientific), CDK6 
(Cell Signaling), CCND1 (EMD Millipore), STAT3 (Cell Signaling), pSTAT3 Y705 (Cell 
Signaling), pTBK1 S172 (Cell Signaling), Akt (Cell Signaling), pAkt T308 (Cell Signaling), 
pAkt S473 (Cell Signaling), pRb S780 (Cell Signaling), pRb S795 (Cell Signaling), and Rb (Cell 
Signaling). Following overnight incubation at 4°C with primary antibody, membranes were 
washed with TBS-Tween and hybridized with mouse and rabbit horseradish peroxidase (HRP)-! 18 
conjugated secondary antibodies (1:5000, GE Healthcare) diluted in TBS-Tween. Protein-
antibody complexes were detected by enhanced chemiluminescence with Amersham ECL Prime 
reagent (GE Healthcare).  
Establishment of tumor xenografts in NSG mice  
CYT387 treatment  
Mouse studies were conducted using Institutional Animal Care and Use Committee 
(IACUC) approved animal protocols in accordance with institutional guidelines at the Lurie 
Family Imaging Center. Tumor xenografts were established using TC32 cells. Approximately 5 
x10
6 cells were suspended in 30% matrigel and subcutaneously injected into 6-week old female 
NSG mice (Jackson Laboratories). Treatments began when tumor volume reached 100-250 mm
3. 
Nine mice were treated with CYT387 at 100 mg/kg daily and ten mice with vehicle. CYT387 
was dissolved in N-methyl-2-pyrrolidone (NMP) at a concentration of 1 mg CYT/10 uL NMP 
and dissolved in a 1:10 ratio in methylcellulose/tween (0.5%) and 0.4% polysorbate-80 in sterile 
water. Treatments were administered by oral gavage, once daily, seven days a week over the 
course of 28 days. Tumor volumes were measured with calipers and animals were sacrificed 
when tumor volumes exceeded 2,000 mm
3. Tumor xenografts were preserved by flash freezing 
as well as formalin fixation for further analysis.  
LEE011 treatment  
Tumor xenografts were established in forty-five NSG mice using 5x10
6 TC32 cells 
resuspended in 30% matrigel and injected into the flank. Treatments began when tumor volume 
reached 100-250 mm
3. LEE011 was resuspended in 0.5% carboxymethylcellulose and delivered 
at doses of 75 mg/kg or 250 mg/kg by oral gavage seven days a week for 21 days. Thirteen mice 
were in the vehicle, 75 mg/kg and 250 mg/kg cohort and three mice per cohort were sacrificed to 
evaluate the pharmacodynamics of the compound following the fifth dose. Tumor volumes were ! 19 
measured with calipers and animals were sacrificed when tumor volumes exceeded 2,000 mm
3. 
Tumor xenografts were flash frozen or formalin fixed for further immunohistochemical staining.  ! 20 
Results:  
 
IKBKΕ scores highly in a near whole genome shRNA screen of Ewing sarcoma  
IKBKΕ is a member of the non-canonical IKK family, along with the closely 
homologous protein TBK1, and is an important regulator of innate immune activity through 
activation of interferon α and β. Both IKBKE and TBK1 have also been shown to affect NF-κB 
signaling and to play a role in cancer cell survival and tumorigenesis.
26,27,38 IKBKE is a putative 
oncogene in breast cancer, with approximately one-third of primary breast cancer samples 
showing copy-number gain of this gene, and amplification of IKBKE is observed in 16.3% of 
breast cancer cell lines.
27 In addition to promoting activation of NF-κB, IKBKE and TBK1 have 
been shown to directly phosphorylate Akt.
23,24 There is also evidence to suggest that IKBKE may 
be important in the cellular response to DNA damage or in the mediating stress response 
associated with oncogene expression through activation of NF-κB.
39,40  
IKBKE was one of the top one hundred hits in the near whole-genome, pooled shRNA 
screen for essential gene liabilities in four EWS/FLI1 expressing Ewing cell lines (Supplemental 
Table 1). Targeting of IKBKE with shRNA led to the preferential depletion of Ewing sarcoma 
cells, as compared to 83 non-similar cancer cell lines. Non-similar cancer cell lines, among those 
tested in Project Achilles, were defined based on lack of gene expression similarity to a 
consensus of published EWS/FLI1 gene signatures
13,34,35 and principle components analysis 
applied on matched gene expression data. In addition to IKBKE, other NF-κB pathway proteins, 
including the canonical IKK, IKBKB and NF-κB1 also scored as top hits in the shRNA screen 
(Figure 1A, B).  
We noted that IKBKΕ protein is expressed as a doublet at levels similar to that expressed 
in MCF-7 breast cancer cells that are dependent on IKBKE (Figure 1C). We then validated the 
dependence of Ewing cell lines on IKBKΕ through shRNA mediated knockdown of IKBKΕ ! 21 
using the second best hairpin from the whole genome shRNA screen as well as two additional 
shRNA sequences, all of which do not target TBK1 or other canonical IKK proteins 
(Supplemental Table 2). Knockdown of IKBKE resulted in impaired viability and decreased 
colony formation across four Ewing sarcoma cell lines (Figure 2). We saw a similar dependence 
of Ewing sarcoma cell lines on the highly-homologous non-canonical IKK protein, TBK1 
(Supplemental Figure 1). TBK1 and IKBKE have similar cellular functions, and dependence on 
both IKBKE and TBK1 has been demonstrated in the context of breast cancer cells, such as 
MCF-7, in which shRNA mediated knockdown of these genes showed that the cell line required 
both genes for proliferation.
27    
Chemical inhibition of IKBKΕ results in impaired viability and colony formation of Ewing 
sarcoma cells  
In addition to evaluating the effect of downregulation of total IKBKΕ protein, as is the 
case with shRNAs, we also investigated the effects of small-molecule inhibition of the kinase 
activity of IKBKΕ on Ewing sarcoma cell growth and colony formation.  
Ewing sarcoma cell lines were treated with MRT67307, a novel inhibitor of 
IKBKΕ/TBK1 and CYT387 a JAK 1/2 inhibitor with activity against IKBKΕ/TBK1.
25,41-43 Both 
of these inhibitors act at the highly conserved kinase domain of the non-canonical IKKs and 
competitively inhibit phosphorylation, with on-target activity of IKBKΕ/TBK1 inhibition 
marked by paradoxical increases in phosphorylation at Serine-172 on TBK1.
25  
We tested the effects of CYT387 and MRT67307 on cell growth and anchorage 
independent growth in a panel of ten Ewing sarcoma cell lines. Cells were treated for five days 
with CYT387 and MRT67307 at a range of concentrations using 2-fold serial dilutions. 
Treatment with CYT387 impaired cell viability in all cell lines, with an average IC50 of 3.95 µM 
(range: 2.07-6.65 µM) (Figure 3B). Similarly, MRT67307 impaired cell viability in all cell lines ! 22 
with an average IC50 of 1.67 µM, ranging between 0.24 µM to 5.66 µM (Figure 3A). There was a 
high degree of similarity between the pattern of sensitive and non-sensitive cell lines to 
MRT67307 and CYT387 (Figure 3A). Ewing cell lines were also treated with Ruxolitinib, a JAK 
1/2 inhibitor, as a control for the effect of inhibition of this pathway on Ewing sarcoma cell 
viability. Ruxolitinib did not inhibit cell viability, with the exception of TC32 and EWS502, 
which had calculated IC50’s of 15.71 µM, and 33.36 µM, respectively (Figure 3C), suggesting 
that the effects of CYT387 on Ewing sarcoma cell viability and anchorage independent growth 
are unlikely to be related to downregulation of JAK signaling.  
We subsequently tested the role of CYT387 to impair colony formation in a 
methylcellulose matrix with continuous exposure to CYT387 over a range of doses from 0 to 10 
µM. Anchorage independent growth was reduced with CYT387 in a concentration dependent 
manner, corresponding to the IC50 of each cell line, with the exception of EWS502, which had 
greater sensitivity to CYT387 as, measured by colony formation than impairment of cell viability 
(Figure 3D).  
On target activity of CYT387 and MRT67307 was assessed with evaluation of p-TBK1 
(S172) levels after treatment of TC32 cells over a time course of 1, 6 and 24 hours. Paradoxical 
elevation of p-TBK1 (S172) is a marker for inhibition of IKBKE and TBK1. p-TBK1 (S172) was 
elevated after one hour of treatment with MRT67307 and CYT387 but not with Ruxolitinib 
treatment (Figure 3E). CYT387 also inhibited JAK 1/2 and resulted in a decrease in p-STAT3 
(Y705), as did Ruxolitinib. The decrease in p-STAT3 levels was noted as early as one hour with 
Ruxolitinib treatment but only after twenty-four hours with CYT387 treatment (Figure 3E). 
We then chose to investigate the role of pharmacologic IKBKE/TBK1 inhibition on 
downstream cellular signaling pathways. Notably, both IKBKE and TBK1 have been shown to 
be oncogenic kinases that promote tumor survival and proliferation through activation of the NF-! 23 
κB pathway. While canonical IKK proteins, such as IKKß, IKKγ and IKKα, have long been 
known to promote NF-κB activation through phosphorylation and downstream ubiquitin-
mediated degradation of the NF-κB inhibitor, IκBα, recent evidence suggests that the non-
canonical IKKs also function in this pathway. In addition to the role of IKBKE and TBK1 in 
innate immunity through IRF-mediated activation of the interferon antiviral response, these non-
canonical IKKs phosphorylate and target IκBα for degradation.
38 Additionally, both TBK1 and 
IKBKE directly phosphorylate and promote nuclear localization of the NF-κB family protein c-
Rel, independently of IKBKB signaling.
44 Following six hours of treatment with CYT387 and 
thirty minutes of stimulation with 30 ng/mL of TNF-α, we noted impaired degradation of IκBα 
as compared with DMSO treated controls in TC32 and HEK-293T cells (Figure 3G). Following 
forty-five minutes of TNF-α stimulation, there was impaired nuclear translocation of NF-κB 
family proteins c-Rel and RelA/p65 in the setting of CYT387 treatment as compared with 
DMSO treated controls in both cell lines (Figure 3G). The effect of CYT387, which acts on 
IKBKE/TBK1, on impairing NF-κB activation was similar to the effect of parthenolide, an 
inhibitor of the canonical NF-κB pathway. However, we also noted mildly impaired nuclear 
translocation of NF-κB p50 in samples treated with CYT387, which was not seen in 
parthenolide, or DMSO treated samples (Figure 3G).  
Additionally, IKBKΕ and TBK1 have been reported to directly promote Akt 
phosphorylation at serine-473 (S473) and threonine-308 (T308), independent of PI-3K, PDK1 
and mTORC2 
23,24. Thus, we evaluated the impact of chemical inhibition with CYT387 and 
MRT67307 on Akt phosphorylation. In contrast to the PI-3K inhibitor, GDC-0941, and an Akt 
inhibitor, MK-2206, we did not observe any effect on p-Akt S473 phosphorylation at six or 
twenty-four hours following treatment with 5 uM of MRT-67307 or CYT387. There was a ! 24 
transient decrease in phosphorylation of the T308 site following six hours of treatment with 
CYT387, MRT-67307 and greater inhibition of T308 phosphorylation with GDC-0941 and MK-
2206, however, this effect was not sustained for the twenty-four hour treatment period with 
either the IKBKE/TBK1 inhibitors or the PI-3K pathway inhibitors (Figure 3F).  
We also noted cytotoxic effects of IKBKΕ/TBK1 inhibition with CYT387 and 
MRT67307, which resulted in the elevation of cleaved PARP-1 and dsDNA breaks as assessed 
with elevation in phosphorylated H2A.X following twenty-four hours of treatment (Figure 3F). 
IKBKE has previously been shown to protect against DNA-damage induced cell death, through 
nuclear localization, DNA-damage dependent SUMOylation and subsequent phosphorylation of 
the NF-κB p65 substrate that promotes expression of anti-apoptotic genes.
40 An impairment of 
IKBKΕ may further exacerbate apoptosis in response to DNA damage in a cellular context, such 
as Ewing, that has been shown to be more sensitive than other tumor types to DNA-damaging 
agents such as camptothecin, cisplatin and mitomycin-C as well as to PARP-1 inhibition.
31,32  
IKBKΕ/TBK1 inhibition in Ewing sarcoma cells results in increased apoptosis but not 
significant G1 cell cycle arrest  
 
We evaluated the mechanism for impairment of cell viability in Ewing sarcoma cells 
following inhibition of IKBKΕ/TBK1 with CYT387 or MRT67307.  We treated two highly 
sensitive Ewing cell lines, SKNEP and TC32, and a relatively less sensitive Ewing line, TC71 
with 5 µM of CYT387 for 24 and 72 hours and measured apoptosis with Annexin V/propidium 
iodide staining. Apoptosis was consistently elevated more than two times control at 72 hours 
after treatment of the SKNEP, TC32 and TC71 cell lines (Figure 4A).  
Next, we evaluated the role of CYT387 and MRT67307 on cell cycle progression with a 
particular eye towards the impact of CYT387 on cell cycle arrest. KINOMEscan assay analysis ! 25 
of CYT387 had been performed in an acellular context. This competitive binding assay involves 
a kinase-tagged phage, test compound and an immobilized ligand to which the kinase is bound. 
Binding of compound to kinase displaces the kinase from the immobilized ligand. The amount of 
kinase bound to immobilized ligand is determined and represented as a percent of DMSO with 
higher values representing decreased interaction between kinase and compound. In this assay, 
interaction of CYT387 and CDK4 was noted, however with less affinity than that between 
CYT387 and IKBKΕ.
45 In vitro treatment of four Ewing cells with CYT387 did result in 
decreased p-Rb S780, a marker of CDK4 inhibition, following one hour of treatment. However, 
this was not noted with MRT67307 (Figure 4B).  
Thus, we also wanted to test the impact of CYT387 on cell cycle arrest, in comparison to 
MRT67307 and LEE011, a highly specific CDK 4/6 inhibitor. We chose one cell line (TC32) 
with high sensitivity to CYT387 and MRT67307 and one cell line (TC71) with relatively 
decreased sensitivity to these compounds. In comparison to treatment with LEE011 where G1 
arrest is observed, we did not observe G1 arrest with these two compounds. Rather, an increase 
in G2 phase was noted with increasing doses of CYT387 and MRT67307 (Figure 4C).  
CYT387 treatment in vivo results in significantly decreased tumor size and prolonged survival 
in a Ewing sarcoma cell line xenograft  
To evaluate the role of IKBKE in vivo, we tested the inhibition of IKBKE/TBK1 with 
CYT387 and demonstrated that CYT387 significantly inhibited tumor xenograft growth of 
established tumors at fifteen days after treatment (p-value = 0.036) and improved survival as 
compared to vehicle control, (p-value = 0.0231) over the course of twenty-nine days of treatment 
(Figure 5A). Mice did not experience any weight loss or other apparent side effects over the 
course of treatment with CYT387 (Figure 5B). Tumor xenografts were frozen and evaluated for 
changes in p-TBK1 (S172) by immunoblotting. Two vehicle treated mice which were sacrificed ! 26 
when tumor volume exceeded 2000 mm^3 on day 16 and 20 and two CYT387 treated mice 
which were sacrificed at day 20 and day 27 were selected for analysis and showed marginal 
elevation of the p-TBK1 S172 mark in the CYT387 treated groups (Figure 5C).  
G1 cell cycle proteins (CDK4, CCND1) score highly in a near whole genome shRNA screen 
G1 cell cycle proteins CDK4 and cyclin D1 (CCND1) also scored among the top ten 
percent of hits in the near whole genome shRNA screen of Ewing cell lines. Targeting of CDK4 
and CCND1, but not CDK6, with shRNAs resulted in preferential depletion of Ewing sarcoma 
cell lines as compared to non-similar cancer cell lines (Figure 6A).  
Cyclin D1 is among the most frequently amplified genes in many cancers and the 
overexpression of cyclin D1 has been associated with shortening of the G1 interval.
46 Ewing 
sarcoma dependency on cyclin D1 and CDK4 is supported by elevated mRNA expression of 
CCND1 and CDK4 in Ewing sarcoma cell lines as compared with cell lines from other tumor 
types (Figure 6D). RNAseq analysis of the Ewing sarcoma cell lines confirms elevation in cyclin 
D1 and CDK4 mRNA levels and is reflective of cyclin D1 and CDK4 expression among a panel 
of twenty-two patient tumors (Figure 6C). Notably, CDK6, which also interacts with cyclin D1 
in regulation of the G1 phase, is poorly expressed across all Ewing sarcoma cell lines and 
primary tumor tissue and did not score within our near-whole genome shRNA screen. 
Additionally, there is evidence to suggest that EWS/FLI1 may engender sensitivity to cell 
cycle inhibition. A large scale screen across 700 cancer lines with the CDK 4/6 inhibitor, PD-
0332991, demonstrated that expression of EWS/FLI1 was a significant marker of increased drug 
sensitivity (p-value = 0.033, calculated by the Mann-Whitney test) (Figure 6B).
47  
To validate the findings of the near-whole genome shRNA screen in Ewing sarcoma cell 
lines, we performed shRNA knockdown of CDK4 and cyclin D1 in two Ewing sarcoma cell 
lines, TC32 and TC71. Knockdown of CDK4 and cyclin D1 resulted in impaired anchorage ! 27 
independent growth and cell viability. Further, we noted a pattern of increased sensitivity among 
TC32 cells for CDK4 and cyclin D1 inhibition as compared with TC71, which was subsequently 
recapitulated in patterns of sensitivity to pharmacologic inhibition of CDK4 (Figure 7).  
 
Pharmacologic inhibition with LEE011, a specific CDK4/6 inhibitor, induces G1 arrest with 
apoptosis in a subset of cell lines 
Following validation of decreased cell viability and impaired anchorage independent 
growth of Ewing sarcoma cell lines in the context of shRNA mediated knockdown of CDK4 and 
cyclin D1, we chose to evaluate the effect of pharmacologic inhibition of CDK4 on Ewing 
sarcoma viability and cell cycle phase with LEE011 (Novartis Oncology), a specific dual 
CDK4/6 kinase inhibitor. We cultured a panel of ten Ewing sarcoma cell lines with a range of 
two-fold serially diluted doses and measured cell viability following five days of treatment. The 
average IC50 across cell lines was 6.48 µM with a range of 0.26 -18.06 µM. There was a group of 
highly sensitive cell lines (TC32, SKNEP, EWS384), with sensitivity at sub-micromolar 
concentrations of LEE011 (Figure 8A, B). Next we evaluated the impact of LEE011 on cell 
cycle phase over a logarithmic concentration curve including concentrations of 0.1 µM, 1 µM 
and 10 µM. G1 arrest was noted in a concentration-dependent fashion with more sensitive cell 
lines arresting at 1 µM or less. The least sensitive cell lines, EW8 and TC71, showed only a 
moderate elevation in the G1 phase following five days of treatment with 10 µM of LEE011 
(Figure 8C). In addition to G1 arrest there is also induction of apoptosis in a subset of cell lines 
highly sensitive to LEE011. Treatment of TC32, SKNEP, EWS834 and RDES with 1 µM of 
LEE011 results in more than a three-fold increase in annexin V staining cells while treatment of 
the least sensitive cell lines, EW8 and TC71, results in little to no induction of apoptosis (Figure 
8D). Finally, we demonstrated in a panel of both relatively sensitive (TC32 and SKNEP) and ! 28 
relatively resistant (TC71 and EW8) cell lines that LEE011 treatment was on-target, resulting in 
decreased pRb-S780, a downstream target of CDK4 activity (Figure 8E).  
 
Effect of in vivo treatment with LEE011  
 
Following in vitro validation of cyclin D1 and CDK4 through small-molecule inhibition 
and shRNA-mediated knockdown, we assessed the efficacy of LEE011 in vivo using a mouse 
xenograft model of Ewing sarcoma. NSG mice injected with subcutaneous xenografts were 
treated with vehicle, 75 mg/kg or 250 mg/kg of LEE011 by daily oral gavage. Toxicity was 
noted at the highest treated dose of 250 mg/kg with one mouse being found dead on day five. An 
additional two mice were noted to be in distress and were sacrificed at ten and twelve days 
following treatment. On necropsy, these mice were noted to have bloated abdomens with the 
intestines and stomach being distended with air, suggestive of a clinical ileus. Mice in the 75 
mg/kg/day group had a mild initial decrease in weight to a nadir of 93% baseline but returned to 
near baseline after receiving a drug holiday and supplemental nutrition and hydration (Figure 7B, 
C). Mice in the 250 mg/kg/day group had a mild but significant weight loss to a nadir of 94% of 
their baseline weight.   
Treatment with LEE011 resulted in marked attenuation of tumor growth at both the 75 
mg/kg (p <0.001) and 250 mg/kg dose (p <0.001) and partial tumor regression was noted at the 
highest treatment dose following fifteen days of treatment (Figure 7A). Although toxicities were 
noted in the high dose group at 250 mg/kg, the 75 mg/kg dose is also effective at attenuating 
tumor growth and closely estimates the clinically relevant dose of 400 – 600 mg/day being 
utilized in clinical trials of LEE011.  
Evaluating mechanisms of sensitivity to LEE011 
 
Within our panel of Ewing sarcoma cell lines there is a range of sensitivity to LEE011 
from sub-micromolar to low micromolar doses. We sought to identify markers of sensitivity to ! 29 
inhibition of CDK4 and evaluated the expression or mutation of several related and regulatory 
proteins. Low expression of p16 (CDKN2A), an inhibitor of the G1 phase cyclins, and high 
expression of Rb, a tumor suppressor that is the target of CDK4/6 phosphorylation, have been 
reported to predict sensitivity to CDK 4/6 inhibition.
48 We tested this hypothesis by evaluating 
the expression of Rb and p16, assessed by RNAseq, in three highly sensitive (IC50 <1 uM at five 
days of treatment) Ewing sarcoma lines as compared to the remaining lines. We noted that p16 
expression was uniformly low and did not significantly vary between the two cohorts (p-value: 
0.634). While Rb expression by RNAseq was significantly (p-value: 0.044) lower in the cohort 
of cell lines with decreased response to LEE011, there was a great deal of variability in Rb 
expression in the three highly sensitive cell lines. Further, endogenous p-Rb levels were similar 
in the most sensitive and least sensitive Ewing sarcoma lines (Figure 8E).  
We next evaluated whether known mutations in the Ewing sarcoma cell lines are 
associated with sensitivity to LEE011 treatment. EWS/FLI1 fusion type was not associated with 
response. Furthermore, the majority of Ewing sarcoma cell lines had loss of p16 and the adjacent 
tumor suppressor p15INK4b (CDKN2B), which binds CDK4/6 and prevents activation by 
cyclinD. These features were also not predictive of sensitivity. Similarly, TP53 was also mutated 
in the majority of Ewing sarcoma cell lines (Figure 10 A). 
Recently, it has been reported that Cyclin D1b, an oncogenic splice variant of cyclin D1, 
is upregulated in several cancers, and its expression associated with increased invasiveness and 
poorer disease outcomes.
49 The aberrant splicing of cyclin D1b results in the loss of regulatory 
regions that influence protein turnover and sub-cellular localization, enhancing its transformative 
potential and nuclear localization. Additionally, the EWS/FLI1 protein has been shown to 
increase cyclin D1b expression through alterations in the dynamics of transcript elongation.
18,19 
We observed variable levels of cyclin D1b mRNA expression as compared to cyclin D1a in a ! 30 
panel of Ewing sarcoma lines. Interestingly, decreased ratios of cyclin D1b/cyclin D1a mRNA 
were noted in cell lines (RDES, TC32, and SKNEP) that have increased sensitivity to LEE011, 
suggesting that cyclin D1b expression may engender resistance to treatment with LEE011 
(Figure 10C). We plan to further test this hypothesis by inducing expression of cyclin D1b in cell 
lines highly sensitive to LEE011 and evaluating the effect on the dose of the small molecule 
required to induce G1 arrest, apoptosis and decreases cell viability.  ! 31 
Discussion: 
 
Ewing sarcoma is a pediatric tumor that despite advances in outcome for patients with 
localized disease continues to have poor outcomes for patients with relapsed or metastatic 
disease.
1,2 As is the case for other pediatric tumors with defining abnormalities of transcription 
factors, Ewing sarcomas have low mutation rates. The tumor driver event is the formation of the 
EWS/FLI1 fusion protein that results in the activation of an aberrant transcriptional program 
involving induction of oncogenes
12,13,15,50,51 and repression of tumor suppressor and mesenchymal 
fate genes.
34,50,52 
Integrative functional genomics approaches, involving genome scale RNAi screens, 
combined with evaluation of gene expression and genomic alterations, can provide insights into 
the biology of Ewing sarcoma. We applied such an approach to Ewing sarcoma to identify novel 
vulnerabilities that are preferentially depleted in EWS/FLI1 expressing cells compared to non-
Ewing sarcoma cancer cells. We have identified novel therapeutic targets and demonstrated the 
importance of non-canonical IKK signaling and G1 cell cycle regulation as mediators of Ewing 
sarcoma cell survival.  
IKBKΕ is a regulator of innate immunity and an oncogenic kinase  
IKBKΕ, along with the highly homologous non-canonical IKK, TBK1, have classically 
been demonstrated to be involved in innate immune responses to viruses through activation of 
interferon expression. Both IKBKΕ and TBK1 are capable of binding to and assembling with 
TRAF3 and TANK to phosphorylate serine and threonine residues on interferon regulatory 
factors 3 and 7 which results in nuclear translocation and production of IFN-α/β.
25,38,53  
The non-canonical IKKs, IKBKΕ and TBK1, can also regulate activation of the NF-κB 
family of proteins, in addition to canonical catalytic IKKs such as IKKα and IKKβ. Like the 
canonical IKK proteins, IKBKE and TBK1 phosphorylate and promote proteasome-mediated ! 32 
destruction of IκBα. However, in contrast to the canonical IKK protein IKBKB, which 
phosphorylates two sites (Ser-32 and Ser-36) on IκBα, IKBKΕ binds to and phosphorylates only 
Ser-36 residue of IκBα while TBK1 uniquely targets only Ser-32 of IκBα.
38 While 
phosphorylation at a single residue with IKBKE has been shown to induce turnover of IκBα
27,54, 
it is possible that IKBKE and TBK1 activity on mediating IκBα destruction is complementary, 
with inhibition of both proteins resulting in greater efficiency of IκBα stabilization.  
IKBKΕ affects other components of the NF-κB signaling pathways.  Exogenous 
expression of IKBKΕ induces RelA/p65 phosphorylation at Ser-536 and accordingly, mouse 
embryonic fibroblasts (MEFs) deficient in IKBKΕ showed decreased phosphorylation at this 
site.
53 However, upon cytokine stimulation, phosphorylation is not entirely lost at this site in 
MEFs deficient in the non-canonical IKKs, suggesting that the canonical IKKs are sufficient to 
maintain phosphorylation at this site.
53  
In addition to phosphorylation and activation of the transactivation domain of RelA/p65, 
IKBKΕ directly activates NF-κB family protein, c-Rel and induces nuclear translocation. Both 
TBK1 and IKBKΕ directly phosphorylate the C-terminal domain of c-Rel, which results in 
dissociation of c-Rel from IκBα, independently of IKKβ signaling.
44  
IKBKΕ has also been shown to peturb NF-κB phosphorylation within the nucleus. 
IKBKΕ expression protects against DNA-damage induced cell death through nuclear localization 
following genotoxic stress. IKBKΕ is then SUMOylated at a lys-231 residue and subsequently 
triggers phosphorylation of nuclear p65, mediating the expression of anti-apoptotic proteins in 
response to DNA damage.
40  
Recent evidence has shown IKBKΕ to be an oncogenic kinase, with its transformative 
and tumorigenic activity mediated through NF-κB pathway signaling. Aldi et. al. first observed 
that IKBKΕ expression was elevated in a number of cancer cells lines including prostate, breast ! 33 
and cervical cancer lines. Expression of IKBKΕ in these cell lines correlated with elevated 
phosphorylation at Ser-536 of p65, while elevation of the catalytic canonical IKKs was not 
correlated, suggesting that IKBKΕ promoted NF-κB activation.
53 More recently, integrative 
genomics approaches have demonstrated that IKBKΕ is a human breast cancer oncogene, 
amplified and overexpressed in a significant percentage of breast cancer cell lines and primary 
tumor specimens.  IKBKΕ was also shown to lead to cell transformation upon overexpression in 
immortalized human cell lines and loss of IKBKΕ in human breast cancer cell lines resulted in 
impaired viability. The mechanism of IKBKΕ mediated transformation was suggested to be 
through activation of NF-κB. ShRNA mediated downregulation of IKBKΕ in breast cancer cell 
lines resulted in suppression of NF-κB target genes, and conversely, overexpression of IKBKΕ in 
human breast epithelial cells resulted in induction of an NF-κB transcriptional profile. 
Furthermore, IKBKΕ overexpression resulted in cytoplasmic degradation of IκBα and primary 
breast cancer specimens showed elevated nuclear localization of c-Rel that was significantly 
associated with the level of IKBKΕ expression.
27  
Additional research has demonstrated that IKBKΕ promotes NF-κB activation through 
multiple effectors. Hutti et. al. utilized an unbiased proteomic approach, involving a positional 
scanning peptide library to identify direct IKBKΕ substrates involved in mediating cell 
transformation.
55 This screen identified serine-418 of tumor suppressor CYLD as a direct target 
of IKBKΕ phosphorylation. Phosphorylation at this site resulted in decreased deubiquitinase 
activity of this protein and facilitated transformation of NIH-3T3 cells. A mutant form of CYLD 
S418A, with an absent IKBKΕ phoshorylation site, was capable of inhibiting IKBKΕ mediated 
NF-κB activation in MCF-7 cells. Inhibition of CYLD by IKBKΕ is relevant and necessary for 
IKBKΕ mediated cellular transformation. CYLD downstream targets for Lys63 linked de-
ubiquitination include inflammatory mediators such as TRAF2, TRAF6 and NEMO. ! 34 
Deubiquitination destabilizes these substrates and inhibits NF- κB mediated inflammatory 
signaling.
55   
Tumor necrosis factor receptor-associated factor 2 (TRAF2), in particular has been 
shown to be an important mediator of NF-κB signaling and is ubiquitinated following TNF-α 
stimulation. Subsequent work has shown that, TRAF2 is an effector of IKBKΕ transformation in 
mammary epithelial cells and that IKBKΕ directly phosphorylates TRAF2, promoting 
subsequent Lys63 mediated ubiquitination and NF-κB activation.
56,57  
IKBKΕ is an essential and targetable kinase in Ewing sarcoma  
IKBKE, a member of the non-canonical IKK family, is an oncogenic kinase that has 
overlapping functions with the highly homologus protein TBK1. As discussed above, there is 
ample evidence demonstrating that the non-canonical IKKs act on several regulatory proteins, 
and integrate numerous pathways to promote tumorigenesis through NF-κB activation.  
Here we used functional genomics approaches to identify IKBKΕ, a known breast cancer 
oncogene, as an essential kinase in Ewing sarcoma. Subsequently, we used both in vitro shRNA 
mediated inhibition and pharmacologic inhibition to demonstrate that IKBKΕ expression and 
activity is necessary for Ewing sarcoma cell survival and anchorage independent growth.  
Additionally, Ewing sarcoma cell lines were highly responsive to two inhibitors 
(MRT67307, CYT387) of IKBKΕ/TBK1, which both demonstrated on-target activity in vitro 
and in vivo. Treatment of NSG mice with Ewing sarcoma xenografts with 100 mg/kg daily of 
CYT387 (a clinically approved JAK1/2 inhibitor with activity against IKBKΕ/TBK1) resulted in 
significantly impaired tumor growth and improved survival without any noted toxicity.  
However, pharmacologic on target activity as assessed by p-TBK1 S172 was only 
marginally elevated at the end of 20 and 27 days of treatment, suggesting that higher doses of 
CYT387 may be necessary to obtain optimal target inhibition or that resistance to therapy may ! 35 
have developed at the dose and schedule tested. A second Ewing sarcoma xenograft study with a 
three-arm design, including vehicle treatment and two doses of CYT387, including treatment at 
the maximum tolerated dose, is warranted.  
We have also demonstrated a potential mechanism of CYT387 activity in Ewing 
sarcoma. We observed that chemical inhibition with CYT387 in a highly sensitive Ewing 
sarcoma line resulted in impairment of nuclear localization of NF-κB family proteins RelA/p65 
and c-Rel, corresponding with attenuation of IκBα degradation following stimulation with TNF-
α. Further, in contrast to parthenolide inhibition in TC32 cells, we also noted impairment in 
nuclear localization of the mature form of NF-κB1 (p50).  
These results suggest that the pharmacologic mechanism of action of CYT387 in Ewing 
sarcoma cells involves impairment of NF-κB activation through inhibition of upstream IKK 
activity. While CYT387 has been shown to be an inhibitor of the non-canonical IKKs, further 
experimentation is necessary to demonstrate whether CYT387 specifically targets the non-
canonical IKK pathway, or whether it also inhibits IKBKB activity, as the markers we evaluated 
for impairment of NF-κB activation are downstream of both the canonical and non-canonical 
NF-κB pathways.  
Additionally, we also showed that CYT387 and MRT67307 inhibition of IKBKΕ/TBK1 
did not inhibit downstream Akt phosporylation but that it did engender cytotoxic stress that 
resulted in elevated PARP-1 cleavage and DNA damage, with elevations in pH2A.X as well as 
subsequent induction of apoptosis.   
Implications for future directions focused on the role of IKBKE in Ewing sarcoma 
Future experiments will focus on characterizing the mechanisms of IKBKE activation in 
Ewing sarcoma as well as the contribution of IKBKE to Ewing sarcoma cell survival as 
compared to TBK1 and other canonical IKK proteins.  ! 36 
A recent study by Zhu et. al. has demonstrated a unique role of CYT387 in inhibition of 
an autocrine signaling loop involved in activating IKBKΕ/TBK1 in KRAS-dependent tumors. 
The study authors demonstrated that IKK-related kinases promote KRAS-driven tumorigenesis 
through the activation of an autocrine loop involving IL-6 and CCL5 which activates STAT3 and 
induces of IKBKΕ/TBK1 resulting in positive feedback with increased expression of CCL5 and 
IL-6 cytokines.
43 This autocrine loop was effectively impaired with CYT387 treatment.  The 
potential role of CCL5 and IL-6 expression in autocrine stimulation of IKBKΕ expression in 
Ewing sarcoma will be investigated, as will the effects of CYT387 treatment on impairing 
expression of CCL5 and IL-6.  
Furthermore, we will evaluate the dysregulation of IKBKΕ-specific downstream 
phosphorylation targets, such as CYLD as well as TRAF2 phosphorylation, in the context of 
chemical perturbation by CYT387 and MRT67307 and shRNA mediated knockdown of IKBKΕ, 
to evaluate whether these pathways which were demonstrated to be necessary in breast cancer 
tumorigenesis are also similarly important in Ewing sarcoma.  
Additionally, since IKBKΕ function can overlap with the catalytic canonical IKK 
proteins, we will further investigate the dependence of Ewing cells on these related proteins and 
subsequent perturbation of NF-κB signaling following shRNA mediated knockdown of these 
proteins. Notably, IKBKB did score highly in our near whole genome shRNA screen, although 
not as highly as IKBKE. To further investigate the contribution of IKBKΕ to cell survival and 
NF-κB signaling in Ewing sarcoma, relative to canonical NF-κB signaling, we plan to develop 
CRISPR-Cas9 mediated knockouts of IKBKΕ in Ewing sarcoma cell lines and evaluate the 
impact of IKBKΕ knockouts on cell survival and on NF-κB signaling, IκBα stabilization, NF-κB 
p65 phosphorylation, c-Rel nuclear localization and IKBKΕ downstream targets, in the setting of ! 37 
endogenous canonical IKK expression. We can further evaluate whether loss of IKBKE can be 
rescued with expression of TBK1 or other catalytic IKK proteins.  
Further, in the near term, small molecule inhibitors of NF-κB signaling can be utilized to 
evaluate if there are potential overlapping dependencies of Ewing sarcoma cells on the canonical 
and non-canonical IKK pathways. For example, we observed that treatment of Ewing sarcoma 
cells with parthenolide, an inhibitor of IKBKB, and CYT387, an inhibitor of IKBKE/TBK1, 
resulted in substantial but not complete impairment of NF-κB nuclear localization by either of 
these inhibitors and combined inhibition of the parallel canonical and non-canonical IKKs with 
these small molecules may be additive or synergistic and should be further evaluated in vitro.   
While we have demonstrated that IKBKE is an essential gene for Ewing sarcoma cell 
survival, these future experiments are necessary to facilitate our understanding of potential 
autocrine mechanisms for IKBKE activation in Ewing sarcoma and to evaluate the contributions 
of canonical and non-canonical NF-κB pathway proteins to the malignant growth of Ewing 
sarcoma tumors.  
The role of G1 regulation in Ewing sarcoma 
 
Through a near whole genome shRNA screen, we have demonstrated that G1 cell cycle 
regulation, namely the activity of cyclin D1 and CDK4, are particularly important in the context 
of cells expressing EWS/FLI1 as compared to other non-similar cancer types. This functional 
genomic data is corroborated by a screen of seven hundred cancer cell lines in which EWS/FLI1 
expressing lines were significantly more sensitive to the CDK 4/6 inhibitor PD-0332991 than 
other tumor types.
47 Overall sensitivity of Ewing tumors to CDK4/6 inhibition may in part be 
related to the role of EWS/FLI1 in directly activating CCND1 gene transcription, resulting in 
increased cyclin D1 expression as compared to other cancer cell lines. ! 38 
We demonstrated that knockdown of cyclin D1 and CDK4 results in impaired cell 
viability and anchorage independent growth in two Ewing sarcoma cell lines. Notably, there was 
increased sensitivity of TC32 to shRNA mediated knockdown of cyclin D1 and CDK4 as 
compared to TC71. This relationship was preserved on pharmacologic inhibition of CDK4 with a 
highly specific CDK 4/6 inhibitor, LEE011. The data presented show that treatment of Ewing 
sarcoma cell lines with LEE011 results in impairment of Rb phosphorylation and significant G1 
cell cycle arrest as well as apoptosis in a panel of highly sensitive lines.   
Finally, in vivo treatment of mouse xenografts with LEE011 demonstrates that this is a 
potential therapeutic strategy for the treatment of Ewing sarcoma. NSG mice with xenografts 
treated at 75 mg/kg/day and 250 mg/kg/day experienced rapid and significant attenuation of 
tumor growth with regression noted in the highest dose arm. The compound was well tolerated at 
the 75 mg/kg/day dose, although mice in the 250 mg/kg/day arm did experience some toxicity. 
This study is ongoing and evaluation of effects of treatment on survival, pharmacodynamics, and 
immunohistochemical staining for markers of cell proliferation and apoptosis will be performed 
on completion of this study.  
We also show that sensitivity to LEE011 mediated CDK4 inhibition is not related to 
variable p16 expression as p16 loss is frequent in the majority of cell lines and p16 expression is 
low throughout the panel of Ewing sarcoma lines tested. A similar pattern of loss was noted with 
CDK2NB. While we noted that at the RNA Rb expression was lower in Ewing lines with 
decreased sensitivity to the drug, endogenous p-Rb levels were similarly elevated in the two 
most highly sensitive and least sensitive lines (Figure 8E). Additionally, CDK4 and cyclin D1 
expres sion are uniformly elevated across the Ewing sarcoma lines. We did note that expression 
of the oncogenic variant of cyclin D1b as compared to cyclin D1a expression was inversely 
correlated with sensitivity to LEE011. We plan to further test this hypothesis by inducing ! 39 
overexpression of cyclin D1b in highly sensitive cell lines and cyclin D1a in less sensitive lines 
and test the effects on cell viability following LEE011 treatment. 
Cell cycle arrest as a therapeutic strategy in cancer  
 
  Inhibition of cell cycle progression through attenuation of CDK activity has long been a 
therapeutic target in cancer, as numerous genetic and epigenetic events result in aberrant activity 
of these proteins.
58,59 Pre-clinical data from the testing of cell cycle inhibitors has demonstrated 
potent cytostatic effects, some apoptotic effects and even tumor xenograft regression associated 
with certain pan-CDK inhibitors like flavopiridol.
60  
However, the therapeutic strategy of cell cycle inhibition has not always yielded results in 
phase I and II trials. For example, Flavopiridol, a pan-CDK inhibitor with activity against cdk1, 
cdk2, cdk4 and cdk7 was shown to induce cell cycle arrest accompanied by apoptosis in non-
small cell lung cancer lines in a p53 independent manner and subsequently was shown to induce 
tumor regression in many solid tumor xenografts.
60 It became the first CDK inhibitor to reach 
clinical trial with disappointing results, prolonging the duration of stable disease in some groups 
of patients, and inducing no notable responses to therapy as a single agent.
58  
Subsequent work has shown sequence specific treatment of cancer with 
chemotherapeutics and cell cycle inhibitors can provide synergy. For example, recruitment of 
cells to the S-phase following pretreatment of cells with non-cytotoxic concentrations of 
chemotherapeutics sensitized cells to subsequent flavopiridol induced apoptosis in an E2F 
dependent manner.
61 
There has been additional development of highly specific CDK inhibitors. CDK 4/6 
inhibitor PD-0332991 was one of the first CDK 4/6 inhibitors to reach clinical trial. Pre-
clinically, it was shown to have anti-proliferative effects on Rb-positive tumor cells and resulted 
in tumor regression of human colon carcinoma xenografts.
62 LEE011, another highly specific ! 40 
CDK 4/6 inhibitor, has recently been shown in pre-clinical models of neuroblastoma to induce 
cytostasis and xenograft growth delay, with increased sensitivity noted in neuroblastoma cell 
lines with MYCN amplification.
63  
Recently, preliminary results from a randomized phase II study of PD-0332991 in 
combination with letrozole versus letrozole alone in patients with ER+/HER2- advanced breast 
cancer showed significant improvement in progression free survival from 7.5 months to 26.1 
months, suggesting synergy between hormone receptor inhibition and cell cycle inhibition that 
was seen in pre-clinical evaluations of PD-0332991 with tamoxifen.
63,64   
The promising results of the combination therapy strategy involving PD-0332991 and 
letrozole, highlight the importance of identifying synergistic relationships between CDK 
inhibitors and standard chemotherapies to derive maximal survival benefits. Furthermore, design 
of optimal therapeutic combinations must take into consideration the role of CDK inhibition in 
inducing pharmacologic quiescence, which can engender resistance to traditional cytotoxic 
chemotherapy and radiation therapy when used in combination.
65  
This has been shown in pre-clinical models in which treatment with CDK 4/6 inhibitors 
prior to treatment with DNA-damaging agents results in attenuation of DNA damage.
65  
Pharamacologic quiescence was also seen in vivo in genetically engineered models of HER2 
driven breast cancer. Tumor bearing mice were treated with PD-0332991 co-administered with 
carboplatin, which resulted in in vivo tumor protection, while both carboplatin and the CDK 4/6 
inhibitor, had activity against the tumor as single agents.
66  
In Ewing, LEE011 has resulted in induction of apoptosis in highly sensitive cell lines, 
there remain a large fraction of cells under G1 arrest that exist in a state of pharmacologic 
quiescence. Additional pre-clinical testing of sequence specific synergy or antagonism between 
cytotoxic chemotherapy and CDK 4/6 inhibition would help inform the development of clinical ! 41 
trials to treat patients with relapsed or metastatic Ewing sarcoma in combination with standard 
chemotherapy regimens. We are currently working in collaboration with the National Center for 
Advancing Translational Sciences (NCATS) at the National Institutes of Health, to conduct high 
throughput screening of sequence-specific combination regimens involving Ewing based 
cytotoxic chemotherapy (adriamycin, vincristine, cyclphosphamide, ifosfamide and etoposide) 
and Ewing specific targeted therapies, such as IGF-1R, mTOR/PI-3K and FAK inhibitors, 
followed by treatment with PD-0332991 to identify potential synergistic regimens that can be 
subsequently validated in vivo and inform future clinical trial design for the translation of this 
inhibitor to the clinic in the treatment of patients with Ewing sarcoma.   
Implications for therapy of Ewing sarcoma 
 
  Through the use of a near-whole genome shRNA depletion screen we have identified and 
characterized novel targetable liabilities for the treatment of Ewing sarcoma. These targetable 
liabilities, IKBKE and CDK4, highlight aspects of Ewing sarcoma tumor biology, notably a 
dependence of NF-κB signaling and EWS/FLI1 associated sensitivity to CDK4/6 inhibition. 
Pharmacologic inhibitors for both IKBKΕ (CYT387) and CDK4/6 (LEE011) are in clinical trials 
for other neoplasms and have shown efficacy in pre-clinical xenograft models for Ewing 
supporting the need to identify highly effective drug combinations with these new targeted 
therapies and the potential for rapid translation of these inhibitors for clinical evaluation in the 
treatment of patients with Ewing sarcoma.  ! 42 
Summary 
 
Ewing sarcoma is the second most common bone tumor that predominantly affects 
children and young adults. Advances in treatment regimens have improved survival for patients 
with localized disease, yielding survival rates of 75% for individuals who receive multi-modality 
therapy with radiation or surgery and a chemotherapy regimen including adriamycin, vincristine, 
and cytoxan alternating with ifosfamide or etoposide.  Despite multi-modality therapy, patients 
with relapsed or metastatic disease have poor survival, underlying the need for the development 
of targeted therapies.  
The biology of Ewing sarcoma is primarily mediated by the expression of a fusion 
protein, either EWS/FLI1 or EWS/ERG, formed by the fusion of chromosome 11 and 22 or 
chromosome 21 and 22. The fusion of EWS with transcription factors FLI1 or ERG, results in 
aberrant gene expression with dual activation of oncogenes and repression of tumor suppressor 
genes, enabling transformation of the Ewing precursor cell.  
To identify genes that promote cell survival and oncogenesis in an EWS/FLI1 dependent 
manner, we performed a genome wide screen to detect genes whose loss results in Ewing 
sarcoma cell death. The list of top genes from this screen was then prioritized based on 
expression in Ewing cell lines and tumors and compared to essential genes in similar and non-
similar cancers to prioritize gene targets whose loss is preferentially lethal in the context of 
EWS/FLI1 expression. We identified a gene involved in NF-κB signaling, IKBKE and mediators 
of G1 cell cycle progression (CDK4 and CCND1) as essential in the context of Ewing sarcoma. 
Next, we showed through genetic suppression of gene expression that IKBKE, CDK4 and 
CCND1 are necessary for Ewing sarcoma cell survival. These results were confirmed by 
pharmacologic inhibition of these targets. Additionally, we showed that treatment of Ewing 
sarcoma cells with small molecule inhibitors of IKBKE resulted in impaired nuclear ! 43 
translocation of NF-κB transcription factors, which promote cell survival and proliferation 
signals. Additionally, inhibition of CDK4 resulted in decreased phosphorylation of the 
downstream tumor suppressor target Rb that then impairs progression of cells through the cell 
cycle inducing arrest of cell division at the G1 checkpoint. Finally, we demonstrated in vivo that 
inhibition of IKBKE and CDK4 with small molecule inhibitors resulted in impairment of tumor 
growth, suggesting that these targets should be further explored for clinical translation and 
development of novel therapies for patients with Ewing sarcoma.  
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Tables and Figures:  
 
Figure 1: IKBKΕ scores as a top hit in a near-whole genome shRNA screen of Ewing cell lines.  A,B. Targeting of IKBKΕ, IKBKB, and NF-
κB1, with shRNAs resulted in preferential depletion of Ewing sarcoma cells as compared to non-similar cell lines. C. IKBKΕ is expressed in the 
majority of Ewing sarcoma cell lines, as a doublet, at levels similar to MCF-7, a breast cancer cell line with dependency on IKBKΕ. 
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Figure 2: Suppression of IKBKΕ impairs cell growth and colony formation.  
A. Panels showing decreased levels of IKBKΕ after infection of Ewing sarcoma cell lines with three unique shRNAs targeting the transcript and 
corresponding impairment in Ewing sarcoma cell growth. Cell growth was measured using a luminescent ATP detection assay and relative 
luminescence was calculated by dividing each timepoint’s luminescent value by the average day 0 luminescent value for each hairpin. B. Colony 
formation in methylcellulose relative to control shRNA. Shown are the means of 14 replicates for viability and 2 replicates for colony formation 
+/- SEM, p-values calculated with student’s t-Test.  
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Figure 3: Small molecule inhibitors of IKBKΕ/TBK1 impair Ewing Sarcoma cell growth and colony formation and induce PARP-1 
cleavage. A, B, C. Effects of five days of treatment with MRT67307 (IKBKΕ/TBK1 inhibitor), CYT387 (JAK1/2 and IKBKΕ/TBK1 inhibitor), 
and Ruxolitinib (JAK1/2 inhibitor) on Ewing sarcoma cell lines. Cells lines were responsive to CYT387 and MRT67307 but not to the JAK1/2 
inhibitor, Ruxolitinib. D. CYT387 inhibits colony formation in a dose dependent fashion. E. CYT387 (5 µM) and MRT67307 (1.5 µM) have on-
target activity in Ewing TC32 cells, with inhibition of IKBKΕ/TBK1 as demonstrated by paradoxical elevation of p-TBK (S172). F. CYT387 and 
MRT67307 do not significantly inhibit AKT phosphorylation, as compared to Akt inhibitor MK-2206 and PI-3K GDC-0941, but there is 
elevation in markers of cytotoxicity and DNA damage evidenced by elevations in pH2A.X and PARP-1 cleavage after treatment with 5 µM of 
compound for 24 hours. G. To evaluate effects of IKBKΕ/TBK1 inhibition on NF-κB signaling in Ewing, TC32 cells were incubated with 
CYT387 for six hours prior to stimulation with TNF-α (30 ng/mL). IκBα degradation was measured by harvesting TC32 cells thirty minutes after 
stimulation with TNF-α. TNF-α stimulation resulted in degradation of IκBα, and this effect was attenuated with CYT387 treatment. 
Parthenolide, an inhibitor of IκBα phosphorylation was used as a positive control. Similar effects of CYT387 activity were seen in HEK-293T 
cells which also express IKBKΕ.
53Nuclear extracts were prepared from TC32 cells harvested following forty-five minutes of TNF-α stimulation. 
Treatment with CYT387 resulted in decreased nuclear localization of NF-κB family proteins RelA/p65 and c-Rel. There was a modest 
impairment of p50 nuclear localization as compared to parthenolide and DMSO controls and no change in p52 nuclear localization. RelB (not 
shown) is not expressed in TC32 cells.  
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Figure 4: Treatment of Ewing sarcoma with CYT387 results in induction of apoptosis but no cell cycle arrest. A. Effects 72 hours of 
CYT387 treatment on SKNEP, TC32, and TC71 demonstrate induction of apoptosis (* p-value = 0.02, ** p-value <0.01). B. CYT387 treatment 
does result in off-target inhibition of CDK4, with downstream dephosphorylation of p-Rb (S780) as compared to the CDK 4,6 inhibitor LEE011. 
C. Despite dephosphorylation of p-Rb (S780), there is no corresponding G1 arrest, but there is a dose dependent increase in G2 and S-phases 
following five days of treatment with MRT67307 and CYT387 in TC71 and TC32 cell lines. 
 
 ! 54 
Figure 5: CYT387 attenuates Ewing sarcoma tumor xenograft growth in vivo and improves survival. A. Tumor volume was significantly 
reduced (Student’s t-test for each time point, p = 0.036) at day fifteen following treatment with 100 mg/kg of CYT387. Mean tumor volumes are 
shown +/- SEM. B. Treatment over the course of twenty-nine days also resulted in improvement in survival, p = 0.0231, as calculated by the 
Mantel-Cox test. There was no difference in the weight of NSG mice over the course of treatment. C. Tumor xenografts of mice treated with 
CYT387 were harvested at time of sacrifice on day 20 and 27 of treatment and frozen. Protein lysates from tumors show a marginal elevation in 
p-TBK (S172) suggestive of on-target CYT387activity.  
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Figure 6: Cyclin D1 and CDK4 score highly in a near whole-genome shRNA screen and are highly expressed in Ewing sarcoma as 
compared to other tumor types. A. Targeting of CCND1 and CDK4 with shRNAs resulted in significant preferential depletion of Ewing 
sarcoma cells as compared to non-similar cell lines with hairpins targeting CCND1 and CDK4 scoring in the top ten percent of depleted hairpins. 
B. Cells expressing EWS/FLI1 have significantly increased sensitivity (p-value 0.033) to the CDK4/6 inhibitor PD-033299. C. RNA sequencing 
of Ewing sarcoma cell lines shows elevated levels of CCND1 (red) and CDK4 (blue), but not CDK6. This pattern of gene expression parallels 
expression in a panel of primary patient tumors of which the average expression is shown in the graph below. D. CCND1 and CDK4 are highly 
expressed in Ewing sarcoma, as measured by mRNA expression, when compared to a panel of other cancer cell lines.  
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Figure 7: Targeting of CDK4 and Cyclin D1 with shRNA mediated knockdown results in impaired cell growth and colony formation. A, 
B, and C. Panels showing decreased levels of CDK4 after infection of Ewing sarcoma cell lines with three unique shRNAs targeting the 
transcript, and corresponding impairment in Ewing sarcoma cell growth and anchorage independent growth. D, E, and F. Decreased levels of 
CCND1 after infection with three unique shRNAs targeting the transcript resulted in downregulation of the protein and impaired cell viability as 
well as anchorage independent growth. Cell growth was measured using a luminescent ATP detection assay and relative luminescence was 
calculated by dividing each timepoint’s luminescent value by the average day 0 luminescent value for each hairpin. The fold change was 
calculated in comparison to the hairpin control. Colony formation was performed in methylcellulose and is shown as fold change relative to 
control shRNA. Shown are the mean of 14 replicates for viability and 2 replicates for colony formation +/- SEM. 
 (Alyssa Kennedy MD, PhD) 
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Figure 8: Pharmacologic inhibition of CDK4/6 in Ewing sarcoma results in impaired cell viability, G1 arrest and apoptosis in a subset of 
highly sensitive cell lines. A, B. Effects of five days of treatment with LEE011 (CDK 4,6 inhibitor) on Ewing sarcoma cell viability 
demonstrates variable sensitivity in the low micromolar range in a panel of Ewing cell lines. C. Treatment along a logarithmic concentration 
range of LEE011 in eight Ewing cell lines, demonstrates potent G1 arrest at less than 1 µM in sensitive lines and minimal increase in the G1 
phase in less sensitive cell lines, TC71 and EW8, following 10 µM concentration for treatment. D. Induction of apoptosis, in addition to cell cycle 
arrest, following CDK4/6 inhibition is noted in the cell lines with increased sensitivity to LEE011. E. LEE011 demonstrates on-target activity 
both highly sensitive and less sensitive cell lines with a decrease in phosphorylation of Rb at Serine-780 (S780).  
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Figure 9: LEE011 impairs Ewing sarcoma tumor xenograft growth in vivo. A. Mice treated with LEE011 at 75 mg/kg and 250 mg/kg 
experienced significantly impaired (Student’s t-test for each time point) tumor growth with mild regression of tumor size noted in the highest 
treatment dose group. B. There was also a modest but significant (Student’s t-test for each time point) dose-dependent decrease in relative weight 
of mice treated with LEE011 over the course of 17 days of treatment, with improvement in weight gain in the 75 mg/kg group following a 
treatment holiday and supportive care involving hydration and supplemental nutrition.  
 
  ! 61 
Figure 10: Putative markers of sensitivity to CDK 4/6 inhibition by LEE011. A. We evaluated the association of EWS/FLI1 (EF) or 
EWS/ERG (EE) expression, as well as EWS/FLI1 fusion type with sensitivity to LEE011. EWS/ERG lines were moderately sensitive to LEE011. 
Three sensitive EWS/FLI1 lines, SKNEP and RDES had the less prevalent fusion type, type II which involves a fusion between exon 7 of EWS 
and exon 5 of FLI1 in contrast to the type I fusion which involves exon 7 of EWS and exon 6 of FLI1. EWS834 has neither a type I or II fusion, 
but a rarer fusion between exon 11 of EWS and exon 8 of FLI1. Despite the prevalence of non-type I fusions in sensitive lines, the most sensitive 
line to LEE011 has a type I EWS/FLI1 fusion. The loss of CDK2NA (blue) or CDK2NB (blue) did not correlate with sensitivity. Complete data 
is not available for TTC466 or EW8 as we only have whole exome sequencing (WES) for these lines.  TP53 mutations are present in the majority 
of all Ewing sarcoma lines. B. We evaluated association between Rb and p16 expression and response to LEE011 by comparing RNAseq RPKM 
values of highly sensitive lines, defined as having sub-micromolar IC50’s, with the less sensitive lines and noted a significant decrease in Rb 
expression in the less sensitive lines. However there is also a great deal of variability in Rb expression amongst the highly sensitive lines. 
Expression of p16 did not correlate with sensitivity. C. The expression of cyclin D1b, the oncogenic isoform of Cyclin D1 has variable expression 
across Ewing cell lines, with a decreased ratio of cyclin D1b to cyclin D1a in cell lines with increased sensitivity to CDK4 inhibition, (highest 
sensitivity lines marked with red asterisk). 
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Supplemental Figure 1: Suppression of a highly homologous protein to IKBKΕ, TBK1, impairs cell growth and colony formation. A. 
Western immunoblots of protein lysates from Ewing sarcoma cell lines infected with three unique shRNAs targeting the TBK1 transcript, and 
resultant suppression of protein expression. B, Suppression of TBK1 protein results in impaired cell growth. Cell growth was measured using a 
luminescent ATP detection assay and relative luminescence was calculated by dividing each days luminescent value from the average day 0 
luminescent value for each hairpin. C. TBK1 knockdown impairs colony formation. Colony formation in methylcellulose relative to control 
shRNA.  Shown are the mean of 14 replicates for viability and 2 replicates for colony formation +/-SEM. 
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Supplemental Table 1: Top 100 essentiality gene hits based on Ewing non-specific and Ewing specific scores. Genes are ranked based on the p-
values assigned by the weighted sum of two hairpins method implemented in RIGER.  
 
#  Ewing non-specific   Ewing vs all  non-Ewing  Ewing vs least Ewing-like 
1  APOBEC3F  STRN4  RASL10B 
2  RPS7  PDXP  CKLF 
3  SNRPE  S100A10  STRN4 
4  RAN  SHPRH  PDXP 
5  RPS13  MINK1  S100A10 
6  RPL23A  PPP1R1A  BIRC2 
7  EIF2S2  BIRC2  IDH1 
8  RPS15A  LATS2  BHLHE41 
9  NHP2L1  AXL  PPP2R4 
10  GRIK1  CKLF  PCDHB3 
11  PCBP2  CTH  HSD17B1 
12  RPS27A  BHLHE41  KCND2 
13  PSMD11  DCLRE1B  MINK1 
14  PSMB2  NEURL  SPR 
15  PSMD1  APEX2  CTH 
16  NUP93  TRERF1  RFPL1 
17  WDR86  GGA2  PCDHA10 
18  NCOR2  DSG2  ADAMTS4 
19  EFTUD2  CD99  LATS2 
20  ZNF439  RFPL1  SHPRH 
21  EIF1AX  PCDHB3  PPP1R1A 
22  PSMA1  IKBKΕ  ISG20 
23  ZNRF2  IL2RG  CIAO1 
24  RPS4X  RASL10B  CAMK4 
25  LSM6  KCND2  YKT6 
26  EIF6  FECH  APEX2 
27  SNRNP200  PCDHA10  DSG2 
28  BAP1  RHBDD2  KATNA1 
29  KCNJ5  ZNF234  CD3E 
30  SNRPD2  IDH1  IL2RG 
31  NCBP1  SPR  FECH 
32  RPS29  AP1M1  C5orf45 
33  RPS9  SRXN1  BCKDHB 
34  EIF5B  WNT10B  TAF7 
35  GREM1  CD8A  HERC1 
36  LSM3  C5orf45  SCN1A 
37  HNRNPU  HIST1H2BL  FKRP 
38  PRPF19  BAP1  ZNF234 
39  PAQR6  AK7  PAX7 
40  RPS8  LYVE1  ABAT 
41  TAF7  VANGL1  APLP2 
42  RPS6  U2AF1L4  BATF ! 64 
43  RPL6  GFRA3  AK7 
44  INPP5F  CD302  NUDT13 
45  RABEP1  PLS1  NEURL 
46  RPS19  PPP2R4  DCLRE1B 
47  SNRPG  SLC1A2  SRXN1 
48  DDX46  FKRP  C4A 
49  ARCN1  KRT28  WNT10B 
50  OSCAR  MYL9  ZNF646 
51  CD82  BCKDHB  VANGL1 
52  LSM5  UQCRFS1  GFRA3 
53  N4BP2  HIST1H2BC  AGPAT3 
54  TAF4B  C4A  TCN2 
55  RPL32  RAB3A  ABCF2 
56  EIF3A  APLP2  AKAP10 
57  SF3B5  ITGB2  GGA2 
58  ADCYAP1R1  AVPR2  ESRRA 
59  ABHD12  KIF12  LTBR 
60  TBC1D25  CAMK4  ITGB7 
61  RPS18  AGPAT3  SMAD4 
62  CDC5L  MECP2  KRT28 
63  POLA1  PRKACB  SGIP1 
64  DDX19B  TCN2  SLC1A2 
65  RUVBL2  ESRRA  HPS3 
66  HNRNPC  CIAO1  CD99 
67  MSR1  HSD17B1  AXL 
68  VPS29  HNRNPH1  AGTR2 
69  ERCC6L  SATL1  COX4I1 
70  TMC7  UCHL3  AP1M1 
71  U2AF1  N6AMT1  LYVE1 
72  ACTL6A  RTCD1  DFNA5 
73  FECH  TCAP  U2AF1L4 
74  NCL  DFNA5  RHBDD2 
75  RPS14  SGIP1  UBE2L6 
76  RPL7  RPS6KA2  SSBP4 
77  ZBTB40  BATF  N6AMT1 
78  EIF4A3  NUDT13  CD180 
79  RNF139  SLC15A3  IMPACT 
80  HAL  CD3E  UCHL3 
81  WBP11  ARHGEF1  SATL1 
82  TIAL1  NECAB2  CD8A 
83  PRKDC  EPHB1  SLC7A3 
84  AFAP1L1  ABCF2  PLK4 
85  ACYP2  KCNJ11  IKBKΕ 
86  RPS17  PRSS21  CAPS 
87  UBB  IMPACT  MXRA5 
88  PRPF3  PFKFB4  RTCD1 
89  CAT  FAM64A  HIST1H2BL ! 65 
90  APOL2  COX4I1  HOXC6 
91  DNAJB2  SCN1A  FABP7 
92  ISL1  ATF6B  DOCK1 
93  POLR2D  PDE4DIP  HGF 
94  EFCAB11  CD180  WSB2 
95  ZNF222  PREX1  OPRD1 
96  RBM17  LPCAT2  IRF5 
97  PSMB6  FGG  AGPS 
98  GRIN1  ICOSLG  ZNF212 
99  SUPT6H  SNX27  TRERF1 
100  EIF3H  EEF1D  TAF9B 
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Supplemental Table 2: List of pLKO.1 shRNA sequences targeting IKBKΕ, TBK1, CDK4, CCND1 
 
  Clone ID  Target Sequence 
shControl    CCTAAGGTTAAGTCGCCCTCGC 
shLuc  TRCN0000072253  ACACTCGGATATTTGATATGT 
shIKBKΕ-3  TRCN0000010036   TGGGCAGGAGCTAATGTTTCG 
shIKBKΕ-5  TRCN0000010027   GAGCATTGGAGTGACCTTGTA 
shIKBKΕ-35  TRCN0000010035   TGCCCACAACACGATAGCCAT 
shTBK1 D5  TRCN0000003182  GCAGAACGTAGATTAGCTTAT 
shTBK1 D8  TRCN0000003185  GCGGCAGAGTTAGGTGAAATT 
shTBK1 D9  TRCN0000003186  CGGGAACCTCTGAATACCATA 
shCDK4-1  TRCN0000000364  GAAATTGGTGTCGGTGCCTAT 
shCDK4-3  TRCN0000000362  ACAGTTCGTGAGGTGGCTTTA 
shCDK4-5  TRCN0000197041  CTCTGAGAGGGCAATCTTT 
shCCND1-1  TRCN0000040038  GCCAGGATGATAAGTTCCTTT 
shCCND1-2  TRCN0000040042  GAACAAACAGATCATCCGCAA 
shCCND1-5  TRCN0000010317  GATTGGAATAGCTTCTGGAAT 
 
 